Dexamethasone Acetate / Palmitate Raw Material For Medicine Manufacturing

Dexamethasone & Dexamethasone-17-acetate & Dexamethasone Palmitate

Basic Details:

Product Name: Dexamethasone
 

Synonyms: Acidocont; Deronil; Dexacortal; dexametona; Flumeprednisolon
 

CAS: 50-02-2
 

MF: C22H29FO5
 

MW: 392.46
 

EINECS: 200-003-9
 

mp: 262-264 °C(lit.)
 

alpha: 75 °(c=1, dioxane)
 

refractive index: 76 ° (C=1, Dioxane)
 

storage temp: 2-8°C
 

solubility ethanol: 1 mg/mL
 

appearance: white solid
 

Water Solubility: 10 mg/100 mL (25°C)
 

Stability: Stable. Combustible. Incompatible with strong oxidizing agents, strong bases, acid

anhydrides, acid chlorides. May be light sensitive

Application:
 

It is usually given by the inhaled route for direct effect on bronchial smooth muscle.This is usually

achieved through a metered dose inhaler (MDI), nebulizer or other proprietary delivery devices

(e.G.Rotahaler or Autohaler).In these forms of delivery, the maximal effect of salbutamol can take

place within five to 20 minutes of dosing, though some relief is immediately seen.It can also be

given intravenously.

Used in the treatment of bronchial asthma, asthmatic bronchitis, emphysema, patients

bronchospasm.

                                    Dexamethasone-17-acetate

Basic Details:

Product Name: Dexamethasone-17-acetate
 

Synonyms: Dexamethason Acetate
 

CAS: 1177-87-3
 

MF: C24H31FO6
 

MW: 434.5
 

EINECS: 214-646-8
 

mp: 238-240 °C(lit.)
 

refractive index: 87 °(C=1, Dioxane)
 

storage temp: 2-8°C
 

appearance: Off-White Solid

Application:
 

Dexamethasone-17-acetate, a corticosteroid, is similar to a natural hormone produced by your

adrenal glands. It often is used to replace this chemical when your body does not make enough of

it. It relieves inflammation (swelling, heat, redness, and pain) and is used to treat certain forms of

arthritis; skin, blood, kidney, eye, thyroid, and intestinal disorders; severe allergies; and asthma.

Dexamethasone-17-acetate is also used to treat certain types of cancer.
 

Dexamethasone-17-acetate comes as a tablet and a solution to take by mouth. Your doctor will

prescribe a dosing schedule that is best for you. Follow the directions on your prescription label

carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take

Dexamethasone-17-acetate exactly as directed. Do not take more or less of it or take it more

often than prescribed by your doctor.

Special Note:
 

Do not stop taking Dexamethasone-17-acetate without talking to your doctor. Stopping the drug

abruptly can cause loss of appetite, upset stomach, vomiting, drowsiness, confusion, headache,

fever, joint and muscle pain, peeling skin, and weight loss. If you take large doses for a long time,

your doctor probably will decrease your dose gradually to allow your body to adjust before

stopping the drug completely. Watch for these side effects if you are gradually decreasing your

dose and after you stop taking the tablets or oral liquid, even if you switch to an inhalation

corticosteroid medication. If these problems occur, call your doctor immediately. You may need to

increase your dose of tablets or liquid temporarily or start taking them again.

                                   Dexamethasone Palmitate

Basic Details:

Product Name: Dexamethasone palmitate
 

Synonyms: DXP;Limethason;Lipotalon
 

CAS: 14899-36-6
 

MF: C38H59FO6
 

MW: 630.87
 

mp: 60-65 °C
 

density: 1.12
 

storage temp: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
 

appearance: Colourless Thick Oil

Description:
 

Dexamethasone palmitate (DXP) is a lipophilic prodrug of dexamethasone (DXM), a potent

corticosteroide used to treat a variety of ophthalmic diseases. The aim of the study was to

characterize the sustained release capacity (in rabbit), efficacy (in rat and rabbit), and safety (in

rabbit, cat, and minipig) of intravitreal (IVT) DXP emulsions in preclinical models.

Application:
 

Oil-in-water emulsions of DXP were administered by IVT injections in rats, rabbits, cats, or

minipigs. Efficacy was assessed in rabbits by the inhibition of VEGF-induced vascular leakage

and in rats by inhibition of laser-induced choroidal neovascularization. Concentrations of DXP

and DXM in aqueous humor, vitreous, retina, choroid, and blood were determined to characterize

the ocular and systemic pharmacokinetic (PK) profile. Complete ophthalmic examinations

(indirect ophthalmoscopy, slit-lamp biomacroscopy, electroretinography, tonometry) were

performed to assess the ocular safety of IVT DXP doses up to 2,600 μg in minipig, followed by

histopathologic examinations. A validated feline model of DXM-induced elevated intraocular

pressure (IOP) was used to assess the ocular hypertensive impact (i.e., the safety) of an IVT

injection of DXP emulsion.